華天科技(002185.SZ):擬出資5.82億元設立控股子公司
格隆匯5月25日丨華天科技(002185.SZ)公吿,公司今日與韶關新區實業集團有限公司(“韶實集團”)簽署《股東出資協議》,雙方擬合計認繳出資9.7億元,在廣東省韶關市設立由公司控股的廣東韶華科技有限公司(暫定名)。其中,公司擬以現金和經評估的設備及知識產權等作價認繳出資5.82億元,佔擬設立公司註冊資本的60%。
本次對外投資是公司根據戰略規劃和經營發展需要,完善公司在珠三角地區產業佈局的重要舉措。擬設立公司主營業務為集成電路封裝測試和顯示器件及顯示模組的生產銷售,該公司的設立能夠進一步擴大公司主營業務的規模,進一步提升公司的整體競爭能力和盈利能力,實現公司持續穩定發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.